Non-genotoxic transplantation and in vivo selection through epitope editing
By
Pietro Genovese
19h agoen
Source
Nature CommunicationsNon-genotoxic transplantation and in vivo selection through epitope editingnature.comNature, Published online: 08 July 2026; doi:10.1038/s41586-026-10737-8 Epitope editing of KIT enables antibody-based, non-genotoxic conditioning that selectively enriches therapeutic BCL11A-edited haematopoietic stem/progenitor cells, supports durable engraftment, preserves clonal diversity and enhances induction of fetal haemoglobin, a therapeutic approach for conditions such as sickle cell disease and β-thalassemia.
You might also wanna read
Crispr-Edited Pancreatic Cells Successfully Transplanted in Type 1 Diabetes Patient for the First Time
For the first time, researchers have successfully implanted Crispr-edited pancreatic cells into a patient with type 1 diabetes. The gene-edi
wired.com·10mo ago
Precision gene editing technologies: From proof-of-concept to clinical therapies
This review article examines the evolution of gene therapy from gene addition to precise genome editing, focusing on breakthrough technologi
cell.com·7d ago
Mutation-dependent responses to sleep and exercise in clonal haematopoiesis - Nature
nature.com·21d ago
Challenges and Innovation for Cell and Gene Therapy: Focusing on Drug Product Formulation, Fill-Finish Processes, and Packaging for These Advanced Therapies
bioprocessintl.com·1h ago
Single Infusion of Gene-Editing Therapy VERVE-102 Shows Promise for Inherited High Cholesterol
An experimental gene-editing therapy called VERVE-102, developed by Verve Therapeutics (a subsidiary of Eli Lilly), shows promise in treatin
discovermagazine.com·1mo ago
Programming the immunological properties of mRNA vaccines for cancer
nature.com·19d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.